Tapering Canakinumab Monotherapy in Patients with Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results from an Open‐label, Randomized Phase IIIb/IV Study

RCT (n=182), found that in patients who achieved a clinical remission (CR) with 4mg/kg canakinumab every 4 weeks, 71% and 84% maintained CR for 24 weeks with a dose reduction to 2mg/kg, and 4mg/kg every 8 weeks respectively.


Arthritis & Rheumatology